ARTICLE | Finance
Under pressure
Why a possible Juno takeout might not be enough to placate Celgene investors
January 19, 2018 10:04 PM UTC
Even if rumored talks by Celgene Corp. (NASDAQ:CELG) to acquire chimeric antigen receptor (CAR) T company Juno Therapeutics Inc. (NASDAQ:JUNO) bear fruit, it still might not be enough to placate buysiders waiting for Celgene to address the Revlimid lenalidomide patent cliff.
Reports of a potential deal surfaced on Tuesday, a week after Celgene said it would acquire Impact Biomedicines Inc. for $1.1 billion up front and up to $5.9 billion in milestones (see BioCentury, Jan. 12). ...